Sferogen D.o.o.

What Sferogen D.o.o. does

Sferogen D.o.o. is a Slovenian pre-clinical biotechnology company founded in 2022 as a spin-off from COBIK, the Centre of Excellence for Biosensors, Instrumentation and Process Control. Operating with 1–10 employees, the company develops vaccine and biologic candidates on two proprietary platforms: nanoSFERIC, a protein nanoparticle technology, and eVLP, an enveloped virus-like particle technology. Disclosed pipeline assets include the nSfCoVac COVID-19 vaccine candidate and a nanoSFERIC-based Nipah virus vaccine, with additional exploratory work spanning oncology, antibacterial therapy, immunomodulation, diagnostics, and veterinary indications. The platforms are designed to enable vaccine development without requiring biosafety level (BSL) facilities, a structural choice with implications for manufacturing capex and partner economics.

The company is pre-revenue, has no disclosed funding rounds or institutional capital raises on record, and operates in founder/management-controlled mode. Its stated go-to-market is enterprise-oriented: the company pursues partnerships with pharmaceutical companies, government health agencies, and healthcare institutions rather than direct commercialization. The business model is therefore expected to monetize via licensing, co-development, or research collaborations against its platform IP, consistent with the typical pre-clinical spin-off trajectory.

As an early-stage entity, Sferogen faces the standard pre-clinical risk profile: dependence on continued founder or grant financing, key-person concentration in a small scientific team, and the need to secure at least one anchor partnership or capital event to validate platform economics. Conversely, the BSL-free manufacturing design, multi-indication optionality, and prioritization of a WHO priority pathogen (Nipah) position the company for public-sector funding channels and partnership-driven upside if pre-clinical milestones are met.

Name

Sferogen D.o.o.

Legal name

Sferogen D.o.o.

Website

https://sferogen.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Sferogen D.o.o. is a Slovenian pre-clinical biotech founded in 2022 as a COBIK spin-off, developing vaccine and biologic candidates on proprietary nanoSFERIC protein nanoparticle and eVLP enveloped virus-like particle platforms for infectious disease, oncology, and other indications.

Ownership category

akta.pro rank

Product category

Vaccine Development and Biotechnology R&D

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

akta.pro secondary industries

Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC), Pandemic Preparedness & Rapid-Response Vaccines (HLAIAEAF), Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK), Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG), Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA) (HLAMAKAH)

Keywords

• Vaccine development services
• Protein nanoparticle platform
• Virus-like particle technology
• Preclinical biotech R&D
• Pandemic preparedness vaccines

Headquarters

HQ city

Ajdovscina

HQ country

Slovenia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Vaccine Development and Licensing: Pre-revenue biotech company developing proprietary vaccine candidates (Nipah virus vaccine, nSfCoVac COVID-19 vaccine) for eventual licensing or partnership with pharmaceutical companies.
2. R&D and Manufacturing Services: Contract R&D and manufacturing services for enveloped virus-like particle vaccines, providing clinical-grade vaccine purity for partners seeking to advance candidates to clinic.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Sferogen develops next-generation vaccine platforms and candidates based on its proprietary nanoSFERIC self-assembling protein nanoparticle technology and enveloped virus-like particle (eVLP) technology. The company is advancing preclinical vaccine candidates including the nSfCoVac COVID-19 vaccine and a Nipah virus vaccine, and offers contract R&D and manufacturing services producing clinical-grade virus-like particle vaccines for partners seeking to advance candidates to the clinic.

Product overview

Sferogen is a biotech company with two core technology platforms: the nanoSFERIC protein nanoparticle platform and the enveloped virus-like particle (eVLP) system. The nanoSFERIC platform enables modular vaccine design with fast antigen switching and scalable production, while the eVLP technology mimics native virions for complete immune responses. Their lead product candidate is nSfCoVac, a COVID-19 vaccine, with additional pipeline development including a Nipah virus vaccine. The company also offers R&D and manufacturing services leveraging their proprietary vaccine production pipeline.

Differentiator

Problem solved

Functional benefit

Brands

• nanoSFERIC: Proprietary self-assembling protein nanoparticle platform with superior immunogenicity for developing next-generation vaccines.
• nSfCoVac
• eVLP

Products and services

• nSfCoVac COVID-19 Vaccine Candidate Lead COVID-19 vaccine candidate developed using enveloped virus-like particle (eVLP) technology, comprising three SARS-CoV-2 structural proteins produced in a high-throughput insect cell line and purified to clinical-grade quality; intended for pharmaceutical partners and pandemic preparedness programs.
• nanoSFERIC Nipah Virus Vaccine Candidate Vaccine candidate for Nipah virus developed on the nanoSFERIC protein nanoparticle platform, targeting a zoonotic virus with annual epidemics, high morbidity and mortality, and no approved vaccine or treatment; intended for pharmaceutical partners and pandemic preparedness stakeholders under a One-Health framework.
• R&D and Manufacturing Services

Quantifiable outcome

• Preclinical studies on mouse model proved immunogenicity on par with approved vaccines for nSfCoVac COVID-19 candidate
• +1 more outcomes

Segments6 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• COBIKcoreStrategic or Co-development Partner · 1 January 2022COBIK is a research and development organization in biotechnology. Sferogen was established in 2022 as a spin-off company from COBIK, making COBIK the originating institution that spun out Sferogen's technology and research capabilities.

Scale indicators2 records

Recent moves7 records

Expansion highlights5 records

Market position

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/sferogen

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sferogen D.o.o.